Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 6, 2004. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Date: September 3, 2004.
- Price Per Share: 1,144.85 pence.
- Treasury Holdings Post-Transaction: 41,318,000 shares.
- Shares in Issue (Excluding Treasury): 5,893,005,397 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2004. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 500,000 share repurchase (500,000 shares x 1,144.85 pence).
- Confirm the impact of the 41,318,000 treasury shares on earnings per share calculations in subsequent reports.
- Review the remaining authorization limit for share buybacks under the May 17, 2004 shareholder resolution.